The plasma membrane is more than a passive boundary. It is organized into dynamic lipid-rich microdomains, often referred to as lipid rafts, that concentrate receptors and signaling molecules. In glioblastoma (GBM), the most aggressive primary brain tumor in adults, the epidermal growth factor receptor (EGFR) signaling is a major oncogenic driver. Yet how tumor cells maintain the membrane platforms that support such proliferative signaling has remained incompletely understood.

A new study published in Life Metabolism by Prof. Junfeng Bi and colleagues at Fudan University identifies CLPTM1L, an endoplasmic reticulum (ER)-localized lipid scramblase, as a regulator of membrane raft formation and EGFR-dependent proliferative signaling in GBM (Figure 1). The work links ER-based lipid remodeling to plasma membrane organization and tumor growth, providing a mechanistic framework for how cancer cells sustain receptor signaling through membrane architecture.

The authors first examined lipid scramblases and flippases in cancer datasets and found that CLPTM1L was frequently gained or amplified and highly expressed across multiple tumor types. In GBM, CLPTM1L expression was higher than in non-tumor brain tissue or low-grade glioma, and high CLPTM1L expression was associated with shorter patient survival in two independent GBM cohorts.

Functional experiments showed that CLPTM1L depletion impaired the viability and proliferation of GBM cell lines and reduced GBM sphere growth, while re-expression rescued the effect. Conversely, CLPTM1L overexpression enhanced colony formation in GBM cells and promoted proliferation in non-cancer RPE1 cells, supporting a role for CLPTM1L in proliferative growth rather than a purely correlative association.

Mechanistically, CLPTM1L loss altered cellular lipid homeostasis and reduced multiple raft-associated components, including glycosphingolipids, phosphatidylserine, and glycosylphosphatidylinositol (GPI)-anchored proteins. The lipid raft marker GM1 was markedly reduced at the cell surface. EGFR, which colocalizes with raft marker GM1, was also reduced at the plasma membrane and redirected toward lysosome-associated puncta, accompanied by suppression of EGFR-mTORC1/2 and ERK signaling. Rescue experiments further indicated that restoring A4GALT, an enzyme involved in Hex3Cer biosynthesis, partially restored EGFR signaling and cell viability in CLPTM1L-depleted cells.

The in vivo data reinforced this model. In an orthotopic GBM xenograft mouse model with inducible CLPTM1L knockdown, depletion of CLPTM1L markedly reduced tumor growth, attenuated EGFR-mTOR signaling in tumor tissue, and prolonged mouse survival. These findings place CLPTM1L upstream of a membrane raft-dependent EGFR signaling axis that contributes to GBM progression.

Overall, the study proposes that CLPTM1L couples ER lipid scrambling and GPI-anchored protein maturation with plasma membrane raft organization, thereby sustaining EGFR signaling in GBM. Because CLPTM1L is amplified or highly expressed in several cancers and many receptor tyrosine kinases rely on membrane organization, CLPTM1L represents a potential therapeutic entry point for targeting membrane-dependent growth signaling (Figure 1).
DOI:10.1093/lifemeta/loag012